Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × peposertib × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

NIH 2 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Cyclophosphamide 215 Radiotherapy 157 Carboplatin 133 pembrolizumab 132 Gemcitabine 126 Nivolumab 123 Paclitaxel 119 fludarabine 102 Cisplatin 102 Dexamethasone 97 Lenalidomide 92 Rituximab 89 Docetaxel 87 Capecitabine 84 Bevacizumab 84 Temozolomide 83 fludarabine phosphate 81 Cytarabine 77 Oxaliplatin 76 Irinotecan 70 Etoposide 69 Filgrastim 68 Melphalan 64 venetoclax 63 Doxorubicin 63 Peripheral Blood Stem Cell Transplantation 62 Fluorouracil 60 Everolimus 58 Radiosurgery 57 durvalumab 55

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡